Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Companyâ€™s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Companyâ€™s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
09/26/09	27.98 $	-2.71%	89,975
06/26/06	28.76 $	-5.02%	2,56,968
05/26/05	30.28 $	-4.66%	1,51,802
04/26/04	31.76 $	+4.40%	2,31,034
03/26/03	30.42 $	-0.75%	2,16,319

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.98USD

Average target price

63.75USD

Spread / Average Target

+127.84%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 01:30:00 10/03/2026 am IST			5-day change	1st Jan Change
27.98 ^USD	-2.71%		-8.71%	+2.60%

14/11	Forte Biosciences Q3 net loss per share improves	RE
14/11	Forte Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Capitalization	50Cr 43Cr 39Cr 37Cr 68Cr 4.6TCr 71Cr 458.84Cr 184Cr 2.2TCr 187.29Cr 183.26Cr 7.89TCr	P/E ratio 2025 *	-6.49x	P/E ratio 2026 *	-7.16x
Enterprise value	50Cr 43Cr 39Cr 37Cr 68Cr 4.6TCr 71Cr 458.84Cr 184Cr 2.2TCr 187.29Cr 183.26Cr 7.89TCr	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	18.51%	Yield 2025 *	-	Yield 2026 *	-

14/11	Forte Biosciences Q3 net loss per share improves	RE
14/11	Forte Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
04/25/04	Forte Biosciences reports inducement grants under Nasdaq listing rules	RE
24/25/24	Certain Common Stock of Forte Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2025.	CI
24/25/24	Certain Options of Forte Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2025.	CI
24/25/24	Certain Pre-Funded Warrants of Forte Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2025.	CI
24/25/24	Certain Restricted Stock Units of Forte Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2025.	CI
15/25/15	Forte Biosciences, Inc. Announces Presentation of Fb102 Celiac Disease Trial At Tampere Celiac Disease Symposium	CI
18/25/18	Guggenheim Initiates Coverage on Forte Biosciences With Buy Rating, $75 Price Target	MT
15/25/15	Forte Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
15/25/15	Tocagen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
30/25/30	Forte Biosciences, Inc.(NasdaqCM:FBRX) added to Russell 3000E Index	CI
30/25/30	Forte Biosciences, Inc.(NasdaqCM:FBRX) added to Russell Microcap Index	CI

04/25/04	Forte Biosciences reports inducement grants under Nasdaq listing rules	RE
18/25/18	Guggenheim Initiates Coverage on Forte Biosciences With Buy Rating, $75 Price Target	MT
02/25/02	Chardan Adjusts Price Target on Forte Biosciences to $61 From $64, Maintains Buy Rating	MT
21/25/21	TD Cowen Initiates Forte Biosciences at Buy	MT
15/24/15	Chardan Boosts Price Target on Forte Biosciences to $64 From $3, Keeps Buy Rating	MT

Forte Biosciences, Inc. Share Price

Equities

FBRX

US34962G2084

Biotechnology & Medical Research

Valuation: Forte Biosciences, Inc.

Chart: Forte Biosciences, Inc.

Latest news: Forte Biosciences, Inc.

Last Transcript: Forte Biosciences, Inc.

Analysts' recommendations: Forte Biosciences, Inc.

Press Releases: Forte Biosciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Forte Biosciences, Inc.

ETFs: Forte Biosciences, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

05/03	Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules	BU
10/02	Forte Biosciences, Inc. to Present at Upcoming Investor Meetings	BU
23/12	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules	BU
25/11	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules	BU
17/11	Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update	AQ

1 day	-2.71%
1 week	-8.71%
Current month	-7.41%
1 month	-6.14%
3 months	+39.27%
6 months	+152.98%
Current year	+2.60%

1 week	27.51	32.97
1 month	26.85	32.97
Current year	21.86	35.62
1 year	4.9	35.62
3 years	4.11	35.62
5 years	4.11	1,089.25
10 years	4.11	1,349.75

Manager	Title	Age	Since
Paul Wagner CEO	Chief Executive Officer	58	01/01/2018
Anthony Riley DFI	Director of Finance/CFO	59	01/03/2020
Christopher Roenfeldt COO	Chief Operating Officer	-	01/10/2020

Director	Title	Age	Since
Paul Wagner CHM	Chairman	58	-
Steven Kornfeld BRD	Director/Board Member	58	01/06/2020
Barbara Finck BRD	Director/Board Member	79	16/03/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
FORTE BIOSCIENCES, INC.	-2.71%	-8.71%	+330.46%	+11.92%	50Cr
ARGENX SE	+1.74%	-0.43%	+20.78%	+98.45%	4.47TCr
WUXI APPTEC CO., LTD.	-2.36%	-5.14%	+45.74%	+12.82%	3.95TCr
INSMED INCORPORATED	+2.14%	-2.18%	+91.12%	+653.32%	3.09TCr
BIONTECH SE	+0.65%	-4.95%	-6.09%	-19.74%	2.56TCr
WUXI BIOLOGICS (CAYMAN) INC.	+3.39%	-1.03%	+54.19%	-29.58%	1.87TCr
GENMAB A/S	+2.49%	-0.03%	+16.00%	-28.35%	1.65TCr
AKESO, INC.	+10.90%	+15.52%	+64.76%	+192.62%	1.22TCr
SUMMIT THERAPEUTICS INC.	+4.04%	-2.90%	-11.59%	+1,007.04%	1.22TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.84%	+17.70%	+68.13%	-	1.13TCr
Average	+2.91%	-4.03%	+67.35%	+210.94%	2.12TCr
Weighted average by Cap.	+2.14%	-3.57%	+38.92%	+190.12%

	2025 *	2026 *
Net sales	-	-
Net income	-6.47Cr -5.58Cr -5.04Cr -4.83Cr -8.77Cr -595.67Cr -9.17Cr -59Cr -24Cr -284.94Cr -24Cr -24Cr -1.02TCr	-8.35Cr -7.21Cr -6.51Cr -6.24Cr -11Cr -769.53Cr -12Cr -77Cr -31Cr -368.11Cr -31Cr -31Cr -1.32TCr
Net Debt	-	-220 -189.77 -171.37 -164.23 -298.49 -20.27T -312.09 -2.02T -811.36 -9.7T -825.86 -808.1 -34.79T